- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01719211
Genetic Basis of Mitral Valve Prolapse (MVP)
November 7, 2023 updated by: Robert A. Levine, MD, Massachusetts General Hospital
The investigators have successfully identified two novel genetic loci for MVP on chromosomes 11 and 13 and are searching for altered genes in these regions.
This requires recruiting large families who may have MVP linked to these or other chromosomes; and obtaining DNA samples from 1,000-1,500 individually affected patients to study the relation between DNA markers throughout the genome and MVP.
It is our expectation that the results of this study will lead to the discovery of gene(s) responsible for MVP.
This will lead to improved understanding of the disease and, in turn, improved ability to treat and prevent progression in genetically susceptible individuals.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This is a genome-wide association study.
Study Type
Observational
Enrollment (Estimated)
1500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Susan Slaugenhaupt, PhD
- Phone Number: 6176433217
- Email: slaugenhaupt@chgr.mgh.harvard.edu
Study Contact Backup
- Name: Robert a levine, MD
- Phone Number: 6177241995
- Email: rlevine@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Mass General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients referred for 2D echo for MVP
Description
Inclusion Criteria:
- Mitral valve prolapse
Exclusion Criteria:
- Other mitral valve diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Discovery of the genetic basis of Mitral Valve Prolapse
Time Frame: 5 years
|
Genome-wide association
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: robert a levine, MD, Mass. General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1999
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
October 30, 2012
First Submitted That Met QC Criteria
October 31, 2012
First Posted (Estimated)
November 1, 2012
Study Record Updates
Last Update Posted (Actual)
November 8, 2023
Last Update Submitted That Met QC Criteria
November 7, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1999-p-007948
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Valve Prolapse
-
NeoChordRecruitingHeart Valve Diseases | Mitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve DiseaseGermany, Greece, Switzerland
-
Lawson Health Research InstituteUnknownMitral Regurgitation | Mitral Valve Prolapse | Mitral Valve Disease
-
Edwards LifesciencesTerminatedMitral Leaflet ProlapseItaly
-
Eric Y. Yang, MD PhDUnknownMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Prolapse | Ventricular Remodeling | Mitral Valve Disease | Degenerative Mitral Valve Disease | Chronic Mitral Disease | Myxomatous Mitral Valve DegenerationUnited States
-
Edwards LifesciencesCompletedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationPoland
-
Edwards LifesciencesCompletedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationPoland
-
Edwards LifesciencesCompletedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationItaly, United Kingdom
-
Edwards LifesciencesTerminatedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationPoland
-
National Heart Institute, EgyptUnknown
-
University of California, San FranciscoNot yet recruitingMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve ProlapseUnited States